Virios Competitors

Delisted . USA . 
Stock . Virios Therapeutics Llc
VIRIDelisted Stock  USD 3.95  0.00  0.00%   
Virios Therapeutics Llc competes with LMF Acquisition, ZyVersa Therapeutics, Sonnet Biotherapeutics, Revelation Biosciences, and Zura Bio; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Virios Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Virios Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Virios Therapeutics competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.203.9714.35
Details
Intrinsic
Valuation
LowRealHigh
0.173.4913.87
Details
Naive
Forecast
LowNextHigh
0.084.2514.63
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
3.274.325.37
Details

Virios Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Virios Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Virios and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Virios Therapeutics Llc does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
CYTO
+ 0.92
ICU
ZVSA
+ 0.91
ICU
SONN
+ 0.9
ICU
CYTO
+ 0.84
ZVSA
CYTO
+ 0.83
NAVB
SONN
+ 0.82
ZVSA
  
High negative correlations   
NAVB
- 0.26
ZURA
IMMX
- 0.24
ZURA

Risk-Adjusted Indicators

There is a big difference between Virios Stock performing well and Virios Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Virios Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
ICU  4.03 (1.09) 0.00 (0.90) 0.00 
 0.00 
 7.98 
(6.93)
 31.31 
ZVSA  3.98 (0.81) 0.00  0.50  0.00 
 0.00 
 7.57 
(9.60)
 78.93 
SONN  4.74 (0.93) 0.00  1.59  0.00 
 0.00 
 12.31 
(9.79)
 37.58 
REVB  3.64 (0.67) 0.00 (0.22) 0.00 
 0.00 
 8.97 
(7.83)
 34.52 
EFTR  7.57 (5.30) 0.00 (0.79) 0.00 
 0.00 
 8.70 
(27.78)
 88.91 
ZURA  3.81 (0.65) 0.00 (0.17) 0.00 
 0.00 
 7.95 
(7.94)
 26.70 
NAVB  6.04 (1.04) 0.00  2.21  0.00 
 0.00 
 12.50 
(12.50)
 40.40 
IMMX  4.34 (0.06)(0.01) 0.08  4.54 
(5.61)
 9.38 
(8.22)
 32.68 
CNSP  4.45 (0.37) 0.00 (0.28) 0.00 
 0.00 
 9.09 
(8.33)
 39.29 
CYTO  3.65 (1.05) 0.00 (4.93) 0.00 
 0.00 
 7.32 
(10.87)
 22.81 
All Fundamental Data

Virios Therapeutics Competitive Analysis

The better you understand Virios Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Virios Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Virios Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
VIRI ICU ZVSA SONN REVB EFTR ZURA NAVB IMMX CNSP
 0.00 
 3.95 
Virios
 1.57 
 2.50 
LMF
 3.60 
 1.07 
ZyVersa
 2.28 
 2.57 
Sonnet
 1.33 
 0.76 
Revelation
 30.00 
 0.13 
Effector
 1.67 
 3.05 
Zura
 9.45 
 0.1 
Navidea
 7.11 
 2.11 
Immix
 8.33 
 0.11 
Cns
Market Volatility
(90 Days Market Risk)
Dangerous
Very risky
Abnormally volatile
Dangerous
Very risky
Very steady
Moderately volatile
Very steady
Risky
Dangerous
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Very High
Average
Very High
Very High
Dangerous
Below Average
Dangerous
Below Average
Very High
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Fairly Valued
Over Valued
Under Valued
Over Valued
Under Valued
Over Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Buy
Strong Buy
Strong Buy
Buy
Not Available
Strong Buy
Not Available
Buy
Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Sell
Strong Sell
Strong Sell
Strong Sell
Not Rated
Sell
Not Rated
Strong Sell
Strong Sell
Current Ratio
4.76
0.38
N/A
1.1
0.68
1.79
N/A
0.22
19.53
12.34
Net Asset
4.17 M
3.51 M
22.11 M
5.43 M
12.21 M
20.54 M
100.84 M
4.37 M
19.93 M
1.7 M
EBITDA
150.9 K
(14.21 M)
(107.74 M)
(18.72 M)
(95.21 K)
(33.73 M)
(60.56 M)
(14.05 M)
(16.14 M)
(18.86 M)
Current Valuation
1.28 M
13.12 M
(611.59 K)
(1.25 M)
9.49 M
(4.52 M)
199.49 M
3.5 M
39.44 M
(503.43 K)
Price To Book
1.37
N/A
0.36
0.82
1.22
13.38
1.3
8.16
3.31
1.92
Operating Margin
N/A
N/A
N/A
-219.69
N/A
N/A
N/A
N/A
N/A
N/A
Retained Earnings
(61.47 M)
(114.73 M)
(103.22 M)
(110.24 M)
(25.47 M)
(179.38 M)
(103.49 M)
(388 M)
(53.41 M)
(69.57 M)
Current Asset
N/A
N/A
N/A
N/A
N/A
N/A
N/A
12.58 M
N/A
6.61 M
Beta
1.58
-1.06
0.64
1.05
0.15
0.83
0.14
1.5
0.1
1.05
Number Of Employees
4
12
7
12
9
14
14
11
14
3
Shares Outstanding
1.11 M
4.46 M
2.34 M
837.66 K
4.29 M
4.7 M
63.77 M
100.08 M
27.51 M
40.75 M
Cash Flow From Operations
(4.87 M)
(10.29 M)
(8.72 M)
(21.34 M)
(7.29 M)
(29.55 M)
(15.05 M)
(8.99 M)
(11.37 M)
(14.14 M)
Total Debt
358.55 K
9.08 M
8.66 K
203.91 K
5.56 M
19.45 M
21.29 M
2.43 M
3.72 M
300.81 K
Return On Equity
-1.2
N/A
-1.52
-2.65
-2.7
-9.47
-0.37
-11.0
-1.04
-10.19
Return On Asset
-0.68
-3.08
-0.25
-0.97
-0.51
-0.83
-0.21
-1.22
-0.57
-2.24
Number Of Shares Shorted
469.93 K
337.06 K
28.89 K
35.2 K
428.6 K
91.62 K
4.96 M
2.69 M
400.7 K
683.26 K
Book Value Per Share
0.11
-7.28
27.33
4.01
0.62
0.21
2.34
-0.011
0.82
-2.97
Current Liabilities
N/A
N/A
N/A
N/A
N/A
N/A
N/A
6.18 M
N/A
488.66 K
Total Asset
4.17 M
3.51 M
22.11 M
5.43 M
12.21 M
20.54 M
100.84 M
4.37 M
19.93 M
1.7 M
Short Ratio
0.64
4.33
0.19
0.03
0.38
0.97
5.43
0.52
2.94
0.04
Target Price
3.0
7.0
20.0
240.0
12.75
11.0
15.0
5.0
7.0
0.5
Debt To Equity
N/A
N/A
N/A
0.36
0.009
1.03
N/A
1.2
0.002
0.013
Shares Owned By Institutions
3.6
4.93
4.47
0.61
2.31
23.71
53.29
1.5
17.64
0.7
Market Capitalization
172.1 K
11.34 M
2.52 M
2.2 M
3.26 M
846.79 K
295.78 M
8.04 M
58.04 M
5.28 M
Price To Earning
N/A
N/A
N/A
N/A
8.69
1.03
N/A
0.53
N/A
-13.7
Price To Sales
N/A
106.52
N/A
39.42
2.88
69.65
N/A
84.14
N/A
N/A
Net Income
(5.3 M)
(26.23 M)
(98.3 M)
(18.83 M)
(120.25 K)
(35.81 M)
(60.56 M)
(15.18 M)
(15.6 M)
(18.85 M)
Earnings Per Share
-5.75
-10.19
491.97
-0.96
-17.53
-12.57
0.57
-0.39
-0.84
-352.97
Shares Owned By Insiders
6.74
8.45
0.61
4.22
0.12
2.9
31.87
35.43
40.09
1.2
Revenue
N/A
N/A
N/A
147.81 K
N/A
N/A
N/A
65.65 K
N/A
N/A
Working Capital
3.81 M
(10.74 M)
(6.84 M)
(786.37 K)
6.58 M
(5.96 M)
80.54 M
(6.74 M)
16.07 M
(4.54 M)
Cash And Equivalents
7.7 M
49 K
N/A
5.22 M
3.48 M
41.04 M
N/A
328.01 K
18.4 M
8.96 M
Cash Per Share
0.92
N/A
N/A
1.21
0.15
0.99
N/A
0.01
1.32
0.22
Gross Profit
N/A
N/A
N/A
(21.09 M)
90.91 M
(19.76 M)
N/A
(119.3 K)
N/A
N/A
Day Typical Price
3.9
2.5
1.07
2.62
0.76
0.12
3.04
0.1
2.16
0.11
Accumulation Distribution
0.11
0.0431
0.0459
0.0551
0.0385
0.59
0.0387
0.11
0.1
0.0833
Market Facilitation Index
0.46
0.11
0.05
0.15
0.03
0.1
0.12
0.012
0.24
0.01
Daily Balance Of Power
N/A
(0.36)
(0.80)
(0.40)
0.3333
0.3
0.4167
(0.87)
0.5833
(1.00)
Period Momentum Indicator
N/A
(0.04)
(0.04)
(0.06)
0.01
0.03
0.05
(0.01)
0.14
(0.01)
Rate Of Daily Change
1.0
0.98
0.96
0.98
1.01
1.3
1.02
0.91
1.07
0.92
Day Median Price
3.87
2.5
1.07
2.65
0.77
0.12
3.04
0.1
2.18
0.12
Price Action Indicator
0.08
(0.01)
(0.01)
(0.11)
N/A
0.025
0.035
(0.01)
N/A
(0.01)
Coefficient Of Variation
(2,499)
(568.57)
(753.78)
(677.78)
(1,366)
(333.16)
(1,375)
(762.99)
6170.25
(2,795)
Mean Deviation
5.85
4.03
3.98
4.74
3.64
7.57
3.81
6.04
4.34
4.45
Jensen Alpha
(0.38)
(1.09)
(0.81)
(0.93)
(0.67)
(5.30)
(0.65)
(1.04)
(0.06)
(0.37)
Total Risk Alpha
(1.78)
(1.85)
(2.45)
(2.15)
(1.38)
(7.10)
(1.21)
(2.50)
(0.93)
(1.39)
Sortino Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
(0.01)
N/A
Downside Variance
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
22.42
N/A
Standard Deviation
8.56
5.37
8.15
6.8
5.72
15.18
5.01
8.36
6.12
6.83
Kurtosis
3.81
2.86
16.03
2.04
7.69
17.04
1.6
0.7251
3.06
2.32
Potential Upside
12.46
7.98
7.57
12.31
8.97
8.7
7.95
12.5
9.38
9.09
Treynor Ratio
(1.38)
(0.90)
0.5039
1.59
(0.22)
(0.79)
(0.17)
2.21
0.0751
(0.28)
Maximum Drawdown
50.54
31.31
78.93
37.58
34.52
88.91
26.7
40.4
32.68
39.29
Variance
73.19
28.85
66.43
46.27
32.73
230.42
25.09
69.93
37.44
46.66
Market Risk Adjusted Performance
(1.37)
(0.89)
0.5139
1.6
(0.21)
(0.78)
(0.16)
2.22
0.0851
(0.27)
Risk Adjusted Performance
(0.02)
(0.13)
(0.09)
(0.10)
(0.05)
(0.22)
(0.05)
(0.09)
0.0211
(0.02)
Skewness
0.4514
(0.53)
0.3811
0.5084
1.75
(3.83)
(0.46)
0.2409
1.32
0.7938
Semi Deviation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
4.54
N/A
Information Ratio
(0.06)
(0.20)
(0.15)
(0.17)
(0.1)
(0.31)
(0.10)
(0.15)
(0.01)
(0.06)
Value At Risk
(10.62)
(6.93)
(9.60)
(9.79)
(7.83)
(27.78)
(7.94)
(12.50)
(8.22)
(8.33)
Expected Short fall
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
(5.61)
N/A
Downside Deviation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
4.74
N/A
Semi Variance
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
20.6
N/A

Virios Therapeutics Competition Performance Charts

Five steps to successful analysis of Virios Therapeutics Competition

Virios Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Virios Therapeutics Llc in relation to its competition. Virios Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Virios Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Virios Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Virios Therapeutics Llc, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Virios Therapeutics position

In addition to having Virios Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Apparel Thematic Idea Now

Apparel
Apparel Theme
Companies manufacturing textile accessories and apparel products. The Apparel theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Apparel Theme or any other thematic opportunities.
View All  Next Launch
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Other Consideration for investing in Virios Stock

If you are still planning to invest in Virios Therapeutics Llc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Virios Therapeutics' history and understand the potential risks before investing.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Bonds Directory
Find actively traded corporate debentures issued by US companies
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY